Stock Fundamentals

Company Information

Company Name
Humacyte Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US44486Q1031
CIK: 0001818382
CUSIP: 44486Q103
Currency: USD
Full Time Employees: 184
Phone: 919 313 9633
Fiscal Year End: December
IPO Date: Aug 26, 2021
Description:

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Address:

2525 East North Carolina Highway 54, Durham, NC, United States, 27713

Directors & Officers

Name Title Year Born
Dr. Laura E. Niklason M.D., Ph.D. Founder, President, CEO & Director 1963
Mr. Dale A. Sander CFO, Chief Corporate Development Officer & Treasurer 1960
Dr. Shamik J. Parikh M.D. Chief Medical Officer 1973
Ms. Sabrina Osborne GPHR, SPHR Chief People Officer NA
Ms. Lisa Molyneux Executive Vice President of Enterprise Planning & Analysis NA
Dr. Heather Connelly Ph.D. Executive Vice President Regulatory Affairs & Quality NA
Mr. Rick McElheny Senior Vice President of Business Development NA
Mr. Jim Mercadante Chief Commercial Officer NA
Dr. Todd E. Rasmussen M.D. Chief Surgical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Aug 20, 2025 Brady W Dougan N/A Sale 591.69K $1.58 $934.86K
Aug 20, 2025 Laura E Niklason N/A Sale 591.69K $1.58 $934.86K
Aug 19, 2025 Brady W Dougan N/A Sale 1.10M $1.63 $1.79M
Aug 19, 2025 Laura E Niklason N/A Sale 1.10M $1.63 $1.79M
Aug 18, 2025 Brady W Dougan N/A Sale 549.36K $1.83 $1.01M
Aug 18, 2025 Laura E Niklason N/A Sale 549.36K $1.83 $1.01M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 12.32M Mar 31, 2026 5.55% $0.00 8.57%
Vanguard Group Inc 8.42M Dec 31, 2025 3.79% $0.00 11.93%
Vanguard Capital Management, LLC 7.16M Mar 31, 2026 3.22% $0.00 0.00%
Antipodes Partners Limited 5.72M Mar 31, 2026 2.58% $0.07 49,039.34%
Great Point Partners LLC 3.75M Mar 31, 2026 1.69% $0.52 0.00%
Geode Capital Management, LLC 3.66M Mar 31, 2026 1.65% $0.00 -1.68%
State Street Corp 3.04M Mar 31, 2026 1.37% $0.00 7.28%
UBS Group AG 2.78M Mar 31, 2026 1.25% $0.00 -6.60%
Woodline Partners LP 2.00M Mar 31, 2026 0.90% $0.00 0.03%
AQR Capital Management LLC 1.92M Mar 31, 2026 0.87% $0.00 5,590.31%
Vanguard Portfolio Management, LLC 1.42M Mar 31, 2026 0.64% $0.00 0.00%
Charles Schwab Investment Management Inc 1.29M Mar 31, 2026 0.58% $0.00 4.18%
Northern Trust Corp 1.22M Mar 31, 2026 0.55% $0.00 6.71%
Susquehanna International Group, LLP 1.06M Mar 31, 2026 0.48% $0.00 4.79%
Vanguard Fiduciary Trust Co 1.01M Mar 31, 2026 0.46% $0.00 0.00%
LPL Financial Corp 864.46K Mar 31, 2026 0.39% $0.00 3.20%
Private Advisor Group, LLC 832.80K Mar 31, 2026 0.38% $0.00 48.30%
The Goldman Sachs Group Inc 677.02K Mar 31, 2026 0.30% $0.00 58.46%
Lion Point Capital, LP 650.00K Mar 31, 2026 0.29% $2.36 30.00%
XTX Topco Ltd 412.09K Mar 31, 2026 0.19% $0.00 -36.69%

Shares Statistics

Shares Outstanding: 269.64M
Shares Float: 196.13M
% Insiders: 750.60%
% Institutions: 2,226.40%
Short % Float: 11.79%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 5.30M 2.74% ▲ 0.00% Apr 30, 2026
2 iShares Russell 2000 ETF 3.97M 2.06% ▲ 0.93% May 29, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 1.81M 0.94% ▲ 6.46% Apr 30, 2026
4 Fidelity Small Cap Index 1.57M 0.81% ▲ 3.52% Mar 31, 2026
5 iShares Biotechnology ETF 1.42M 0.73% ▲ 1.95% May 29, 2026
6 iShares Russell 2000 Value ETF 1.11M 0.57% ▲ 0.00% May 29, 2026
7 Fidelity Extended Market Index 1.01M 0.52% ▲ 81.38% Apr 30, 2026
8 State St Russell Sm/Mid Cp® Indx SL Cl I 957.62K 0.50% ▲ 0.00% May 31, 2026
9 Vanguard Russell 2000 ETF 817.36K 0.42% ▲ 2.12% Apr 30, 2026
10 Russell 2000 Equity Index Fund B 814.75K 0.42% ▲ 0.17% Dec 31, 2025

Valuation Metrics

Enterprise Value: $208.16M
Trailing P/E: 0.00
Forward P/E: 35.84

Financial Highlights

Market Cap: $187.05M
EBITDA: $-105.19M
Book Value: $0.05
Earnings/Share: $-0.63
Profit Margin: 0.00%
Operating Margin: -5,704.04%
ROA (TTM): -51.49%
ROE (TTM): -409.47%
Revenue (TTM): $2.02M
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -4.30%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.69x 12.18x 0.97x -9.55x -1.70x
2024-12-31 2.40x -0.06x 1.38x -12.33x -0.02x
2023-12-31 4.52x 3.04x 0.89x -15.16x -0.43x
2022-12-31 7.88x 0.27x 0.43x -13.64x 12.77x
2021-12-31 20.75x 0.24x 0.57x -18.68x -2.12x
2020-12-31 3.69x 0.07x 0.34x -29.34x -0.09x
2019-12-31 8.76x 0.02x 0.22x -37.29x -0.04x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HUMA.US!